Tonix Pharmaceuticals Holding Corp
NASDAQ:TNXP 4:00:00 PM EDT
Products, Regulatory
Tonix Pharmaceuticals Reports Topline Results From Phase 3 Recovery Study Of TNX-102 Sl In PTSD And Outlines Future Development Plans
Published: 12/21/2020 12:23 GMT
Tonix Pharmaceuticals Holding Corp (TNXP) - Tonix Pharmaceuticals Reports Topline Results From Phase 3 Recovery Study of Tnx-102 Sl in Ptsd and Outlines Future Development Plans.
Tonix Pharmaceuticals Holding Corp - Primary Endpoint for Full Cohort of Enrolled Participants Did Not Achieve Statistical Significance.
Tonix Pharmaceuticals Holding Corp - Encouraging Activity of Tnx-102 Sl Observed in Secondary Endpoints.
Tonix Pharmaceuticals Holding Corp - Tnx-102 Sl Generally Well Tolerated; No New Safety Signals Observed: No Change in Weight Or Blood Pressure.
Tonix Pharmaceuticals Holding Corp - Planning Development of Tnx-102 Sl for Treatment of Ptsd Sleep Disturbance Indication, Pending FDA Discussion.
Tonix Pharmaceuticals Holding Corp - Primary Endpoint for Full Cohort of Enrolled Participants Did Not Achieve Statistical Significance.
Tonix Pharmaceuticals Holding Corp - Encouraging Activity of Tnx-102 Sl Observed in Secondary Endpoints.
Tonix Pharmaceuticals Holding Corp - Tnx-102 Sl Generally Well Tolerated; No New Safety Signals Observed: No Change in Weight Or Blood Pressure.
Tonix Pharmaceuticals Holding Corp - Planning Development of Tnx-102 Sl for Treatment of Ptsd Sleep Disturbance Indication, Pending FDA Discussion.